PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24114663-5	2014	The activation of mitogen-activated protein kinases (MAPKs) was blocked by ISO, and NF-kappaB nuclear translocation was decreased by ISO both alone and together with NF-kappaB inhibitor (PDTC) and MAPKs inhibitors (U0126, SP 600125, and SB 203580).	pyrazolanthrone	222-231	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	166-175	
25084093-12	2014	Importantly, an inhibitor of phospho-JNK, SP600125, protects against OGD-Rep induced apoptosis and inhibited NF-kappaB signaling pathway, similar to the roles of ginsenoside Rb3.	pyrazolanthrone	42-50	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	109-118	
24114663-5	2014	The activation of mitogen-activated protein kinases (MAPKs) was blocked by ISO, and NF-kappaB nuclear translocation was decreased by ISO both alone and together with NF-kappaB inhibitor (PDTC) and MAPKs inhibitors (U0126, SP 600125, and SB 203580).	pyrazolanthrone	222-231	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	84-93	
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	pyrazolanthrone	16-25	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	122-131	
19508391-6	2009	Further, LPS + IFNgamma-induced expression of iNOS and Nox1 was attenuated by the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor PD98059, the JNK inhibitor SP600125, the Jak2 inhibitor AG490 and the NFkappaB inhibitor MG132, but not by the p38 mitogen-activated protein kinase inhibitor SB203580.	pyrazolanthrone	172-180	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	215-223	
20026063-4	2010	All specific NFkappaB and MAPKs pathway inhibitors (pyrrolidine dithiocarbamate, AG490, U0126, SB203580 and SP600125) remarkably attenuated NO production induced by the beta-glucan.	pyrazolanthrone	108-116	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	13-21	
20167866-6	2010	LTA-stimulated NF-kappaB translocation or cPLA(2) phosphorylation was attenuated by pretreatment with LY294002, SB202190, U0126, or SP600125.	pyrazolanthrone	132-140	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	15-24	
18049903-7	2008	Moreover, hypoxic exposure (90 min) increased the level of nuclear factor-kappa B (NF-kappa B) phosphorylation, which was blocked by a pretreatment with SB 203580 (p38 MAPK inhibitor) or SP 600125 (JNK inhibitor).	pyrazolanthrone	187-196	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	59-81	
18049903-7	2008	Moreover, hypoxic exposure (90 min) increased the level of nuclear factor-kappa B (NF-kappa B) phosphorylation, which was blocked by a pretreatment with SB 203580 (p38 MAPK inhibitor) or SP 600125 (JNK inhibitor).	pyrazolanthrone	187-196	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	83-93	
34703220-11	2021	Moreover, the JNK inhibitor SP600125 also reduced the level of NF-kappaB phosphorylation induced by PM2.5.	pyrazolanthrone	28-36	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	63-72	
33918237-6	2021	Application of inhibitors for ERK (PD98059) and JNK (SP600125) abolished the LPS-induced effect on NF-kappaB p65 phosphorylation, which indicated that ERK and JNK signaling pathways were involved in CBN-mediated inhibition of NF-kappaB activation.	pyrazolanthrone	53-61	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	99-108	
28498464-5	2017	Furthermore, S100A8/A9 markedly enhanced the nuclear translocation of NF-kappaB p65 and the DNA-binding activities of NF-kappaB in BV-2 microglial cells, and suppression of ERK and JNK/MAPK signaling pathways by PD98059 or SP600125 significantly inhibited NF-kappaB activity and the release of TNF-alpha and IL-6 in the S100A8/A9-treated BV-2 microglial cells.	pyrazolanthrone	223-231	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	70-79	
32230861-7	2020	The specific MAPK inhibitors, U0126, SP600125, and SB203580, suppressed LPS-stimulated pro-inflammatory mediators, cell migration, and NF-kappaB nuclear translocation, indicating that MAPKs may be the upstream kinase of NF-kappaB signaling.	pyrazolanthrone	37-45	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	135-144	
32230861-7	2020	The specific MAPK inhibitors, U0126, SP600125, and SB203580, suppressed LPS-stimulated pro-inflammatory mediators, cell migration, and NF-kappaB nuclear translocation, indicating that MAPKs may be the upstream kinase of NF-kappaB signaling.	pyrazolanthrone	37-45	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	220-229	
27121155-7	2016	Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.	pyrazolanthrone	47-55	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	147-156